Semaglutide and Liraglutide injectables added to ADIoS
Posted in Announcement, News
In response to MHRA inspection requirements that NHS Trusts should have a system to monitor changes in usage trends of GLP-1 agonists to identify diversion, Rx-info has added Semaglutide and Liraglutide injections as monitored drugs in ADIoS.
Reporting of these items will become visible to ADIoS subscribers from 30/8/24.
These drugs are added to the ADIoS risk list and joins other controlled and diversion risk medicines.
If you are interested in understanding how ADIoS can support your organisation in monitoring medicines with abuse potential please email us [email protected] or take a look at our ADIoS – RX-Info page.